Biologically Active Substance
Merck Secures $2B Deal with China’s Hengrui for Novel Heart Drug
Merck, Hengrui Pharmaceuticals, HRS-5346, Lipoprotein(a) inhibitor, cardiovascular disease, licensing agreement
Immunovant Shifts Focus to Next-Gen Drug Despite Positive Phase 3 Results for Batoclimab in Myasthenia Gravis
Immunovant, batoclimab, myasthenia gravis, Phase 3 success, IMVT-1402, FcRn inhibitor, autoimmune disorders
Avidity’s Del-zota Shows Promise in Duchenne Muscular Dystrophy Treatment
Del-zota, Duchenne muscular dystrophy (DMD), RNA therapeutics, exon 44 skipping, dystrophin production, creatine kinase reduction, safety profile
Lonza’s Vision for the Future: A Fireside Chat with New CEO Wolfgang Wienand
Lonza, Wolfgang Wienand, CDMO, Pharmaceutical manufacturing, Biologics, Cell and gene therapy, Small molecules, Leadership transition, Industry outlook
Incyte’s oral HS drug hits study goals, but fails to excite investors
povorcitinib, JAK1 inhibitor, hidradenitis suppurativa, Phase 3 trials, efficacy, investor reaction, regulatory submission
FDA’s medical review departments remain largely untouched (for now) by Musk-led cuts
FDA, medical review, drug approval, device regulation, staff cuts, Elon Musk, DOGE, government efficiency
Viking Therapeutics Signs $150 Million Manufacturing Deal with CordenPharma for Obesity Drug VK2735
Viking Therapeutics, CordenPharma, VK2735, Obesity drug, GLP-1/GIP dual agonist, Contract manufacturing, API production, Fill/finish capacity, Subcutaneous and oral formulations
Sotyktu Shows Promise in Phase 3 Psoriatic Arthritis Trial
Sotyktu, deucravacitinib, psoriatic arthritis, Bristol Myers Squibb, POETYK PsA-2 trial, TYK2 inhibitor
Novo’s Studies of GLP-1s for Addiction Limited to Ongoing Phase II
GLP-1, addiction treatment, semaglutide, clinical trials, Novo Nordisk
FDA Approves First Treatment for Macular Telangiectasia Type 2 (MacTel)
ENCELTO, revakinagene taroretcel-lwey, MacTel, FDA approval, encapsulated cell therapy, ciliary neurotrophic factor (CNTF)